



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Date: February 14, 2025

**To,
The General Manager,
Corporate Relationship Department,
BSE Limited,
Phiroz Jeejeebhoy Tower,
Dalal Street, Mumbai — 400001,
Maharashtra, India**

Reference : ISIN - INE331C01017 Scrip Code-524661; Symbol- WELCURE

Sub: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024

Pursuant to Regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, we hereby submit the Integrated filing (Financials) for the quarter and nine months ended December 31, 2024.

This is for information and records.

Thanking You,
Yours Faithfully,

FOR, WELCURE DRUGS & PHARMACEUTICALS LTD.

**SURAJ CHAGAN SOLANKI
DIRECTOR
DIN- 10380845**

CHANDABHOY & JASSOOBHOY

CHARTERED ACCOUNTANTS

CA GAUTAM N. SHAH
CA RAHUL G. DIVAN
CA NIMAI G. SHAH

PHONE : (079) 26586063 / 26586069
CELL : 98242 56190 / 98247 99760
E-MAIL : cnjabd@gmail.com
cnjabd@yahoo.com

No. 605-606-607, Silver Oaks, Nr. Mahalaxmi Cross Roads, Paldi, Ahmedabad-380 007, INDIA.

Limited review report

Review report to:

The Board of Directors

WELCURE DRUGS & PHARMACEUTICALS LTD.

We have reviewed the accompanying statement of unaudited financial results of WELCURE DRUGS & PHARMACEUTICALS LTD. (hereinafter referred to as the "Company") for the quarter ended 31st December, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMDI/80/2019 dated 19th July, 2019.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Basis for disclaimer of opinion:

As informed by the Director and various points pertaining to various elements of the financial statements as mentioned below may require necessary adjustments / disclosures in financial statements and may have material and pervasive impact on the financial position of the Company for the quarter ended as at 31st December, 2024. The books of account of the company have been prepared on going concern basis. Accordingly, pending following adjustments and unavailability of sufficient and appropriate audit evidence, we are unable to express our opinion on the attached financial statements of the Company.



1. During the time of audit, we have not been provided with satisfactory supporting documents for completeness of transactions related to Sales and Purchase, value of inventory, third party balance confirmation of trade receivables and payable alongwith related tax compliances thereof outstanding as on 31st December,2024 in the financial results. Therefore, We could not obtain appropriate audit evidences for the aforesaid matters.
2. During the time of audit, we have not been provided with the fixed assets register. Due to lack of documents and workings, we could not verify the correctness of depreciation and deferred tax liabilities/assets.

Based on our review conducted as above, apart from the aforesaid observations, nothing has come to our attention, apart from the matters reported under Basis for Disclaimer of opinion that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19th July, 2019, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the accompanying financial results and other financial information for the quarter ended 31st December,2023 which has been presented solely based on the information compiled by the Management and has been approved by the Board of Directors.

For Chandabhoy & Jassoobhoy

Nimai Gautam Shah

CA Nimai Gautam Shah
Partner

Chartered Accountants
Membership No : 100932
FRN No : 101648W



Place : Ahmedabad

Date : 14-02-2025

UDIN : 25100932BMHUCX8959

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN:L24232DL1996PLC227773

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31/12/2024						
Particulars	[RUPEES IN MILLIONS]					
	Three Months Ended on 31.12.2024	Three Months Ended on 30.09.2024	Corresponding Three Months ended in the previous year 31.12.2023	Year to date figures for current period ended on 31.12.2024	Preceding year to date figures for period ended on 31.12.2023	Previous Year ended 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	88.380	245.500	-	333.880	-	-
2. Other Income	-	-	0.349	-	0.349	0.939
3. Total Revenue (1+2)	88.380	245.500	0.349	333.880	0.349	0.939
4. Expenses						
Cost of Materials consumed	-	-	-	-	-	-
Purchase of stock-in-trade	-	1,640.270	-	1,640.270	-	-
Change in inventories of Finished Goods, Work-in-Process and Stock-in-Trade	73.816	(1,435.236)	-	(1,361.420)	-	-
Employees benefits expenses	1.145	0.970	0.512	2.642	0.782	0.875
Finance Cost	-	-	-	-	-	-
Depreciation and Amortisation expense	0.048	0.056	0.050	0.124	0.150	0.359
Other Expenses	4.234	21.058	0.065	28.192	0.972	1.453
Total Expenses	79.243	227.118	0.627	309.808	1.904	2.687
5. Profit before exceptional and extraordinary items and tax (3 - 4)	9.137	18.382	(0.278)	24.072	(1.555)	(1.748)
6. Exceptional Items	-	-	-	-	-	-
7. Profit before extraordinary items and tax (5 - 6)	9.137	18.382	(0.278)	24.072	(1.555)	(1.748)
8. Extraordinary items	-	-	-	-	-	-
9. Profit before tax (7 - 8)	9.137	18.382	(0.278)	24.072	(1.555)	(1.748)
10. Tax Expenses	-	-	-	-	-	-
a) Current Tax	5.000	-	-	5.000	-	-
b) Deferred Tax	(0.008)	-	-	(0.008)	-	-
11. Profit/(Loss) for the period from continuing operations (9 - 10)	4.145	18.382	(0.278)	19.080	(1.555)	(1.748)
12. Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
13. Tax expense of discontinuing operations	-	-	-	-	-	-
14. Profit/(Loss) from Discontinuing operations (after tax) (12-13)	-	-	-	-	-	-
15. Profit/(Loss) for the period (11 + 14)	4.145	18.382	(0.278)	19.080	(1.555)	(1.748)
16. Other comprehensive income net of taxes	-	-	-	-	-	-
17. Total comprehensive income for the period (15+16)	4.145	18.382	(0.278)	19.080	(1.555)	(1.748)
18. Paid -up equity share capital(Face Value of Rs.10/-Per Share)	1,124.391	1,124.391	134.391	1,124.391	134.391	134.391
19.i Earing Per Share(EPS) (before extraordinary items) (Of Rs. 5/- each) (Not annualised except last column)						
(a) Basic	0.037	0.163	(0.002)	0.170	(0.116)	(0.130)
(b) Diluted	0.037	0.163	(0.002)	0.170	(0.116)	(0.130)
ii Earing Per Share(EPS) (after extraordinary items) (Of Rs. 5/- each) (Not annualised except last column)						
(a) Basic	0.037	0.163	(0.002)	0.170	(0.116)	(0.130)
(b) Diluted	0.037	0.163	(0.002)	0.170	(0.116)	(0.130)

Notes :

- The Chairman and Managing Director of the Company has been identified as the Chief Operating Decision Maker (CODM) as defined by IND AS 108, " Operating Segments". The Company operates in one segment only i.e. " Manufacturing of Steel, Non-Alloys Steel and Alloys Steel Casting". The CODM evaluates performance of the Company based on revenue and operating income from "Manufacturing of Steel, Non-Alloys Steel and Alloys Steel Casting". Accordingly, segment information has not been separately disclosed.
- The above mentioned Unaudited Financial Results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 14th February,2025
- The aforesaid Financial Results for the quarter ended on December 31, 2023 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments thereof.
- The Statutory Auditors have carried out limited review of the above Financial Results for the quarter ended 31st December, 2024.
- Previous period's figures have been regrouped/rearranged wherever necessary, to confirm to the current period's classification.

DATE :- 14.02.2025

FOR WELCURE DRUGS & PHARMACEUTICALS LTD.

SURAJ CHAGAN SOLANKI
DIRECTOR
DIN: 10380845



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. –

Name of listed entity	Welcure Drugs & Pharmaceuticals Limited
Mode of Fund Raising	Preferential Issue
Date of Raising Funds	July 18, 2024 (Date of Allotment)
Amount Raised	<ul style="list-style-type: none">• On Allotment of Fully Convertible Warrants Rs. 24,75,00,000/-• On Conversion of 3,29,99,997 Warrants into equal number of equity shares- Rs. 24,74,99,977.50/-• On Conversion of 3,29,99,997 Warrants into equal number of equity shares- Rs. 24,74,99,977.50/-• On Conversion of 3,30,00,006 Warrants into equal number of equity shares- Rs. 24,75,00,045/-
Report filed for Quarter ended	31st December, 2024.
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	-
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	-
Comments of the auditors, if any	-



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Original Object	Modified Object, if any	Original Allocation	Modified Allocation, if any	Funds Utilised	Amount of Deviation/ Variation for Quarter according to applicable object	Remarks, If any
Working capital requirements, including repayment or prepayment thereof, meeting various expenditure of the Company including contingencies;; (b) capital expenditure, including towards development, refurbishment and renovation of our assets (c) any other cost incurred towards the main business objects of the Company; and (d) financing of business opportunities, strategic initiatives; and/ or (e) general corporate purpose	No	Rs 99,00,00,000	Nil	Rs.99,00,00,000	Nil	-



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Deviation or variation could mean:

- a. Deviation in the objects or purposes for which the funds have been raised or
- b. Deviation in the amount of funds actually utilized as against what was originally disclosed or
- c. Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

C. Format for Disclosing Outstanding Default on Loans and Debt Securities: There is no default on loans and debt securities during the Quarter ended December 31,2024.

D. Format for Disclosure of Related Party Transactions (applicable only for half yearly filings i.e., 2nd and 4th quarter) - Not Applicable.

E. Statement on Impact of Audit Qualifications (for Audit report with Modified Opinion) submitted Along-with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing I.e., 4th quarter) - Not Applicable.

FOR, WELCURE DRUGS & PHARMACEUTICALS LTD.

**SURAJ CHAGAN SOLANKI
DIRECTOR
DIN- 10380845**